Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST – Get Free Report) have been assigned an average rating of “Moderate Buy” from the six research firms that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $7.25.
A number of research analysts have recently commented on the stock. Wells Fargo & Company cut their price target on shares of Milestone Pharmaceuticals from $8.00 to $7.00 and set an “overweight” rating on the stock in a report on Thursday, May 14th. Wall Street Zen cut shares of Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Sunday, May 17th. Zacks Research downgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Friday, May 15th. Finally, Raymond James Financial began coverage on shares of Milestone Pharmaceuticals in a research note on Friday, April 10th. They issued a “strong-buy” rating and a $6.00 target price on the stock.
Read Our Latest Report on MIST
Insider Activity
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of MIST. Orbimed Advisors LLC bought a new position in Milestone Pharmaceuticals during the 3rd quarter worth about $6,444,000. Marshall Wace LLP raised its holdings in shares of Milestone Pharmaceuticals by 289.8% in the 4th quarter. Marshall Wace LLP now owns 1,656,821 shares of the company’s stock valued at $3,347,000 after purchasing an additional 1,231,793 shares in the last quarter. Pathstone Holdings LLC bought a new stake in shares of Milestone Pharmaceuticals in the 3rd quarter valued at about $2,000,000. Boxer Capital Management LLC purchased a new stake in shares of Milestone Pharmaceuticals in the 3rd quarter worth approximately $1,333,000. Finally, Two Sigma Investments LP purchased a new stake in shares of Milestone Pharmaceuticals in the 3rd quarter worth approximately $1,333,000. 86.18% of the stock is currently owned by hedge funds and other institutional investors.
Milestone Pharmaceuticals Price Performance
MIST opened at $1.30 on Wednesday. The business has a fifty day moving average of $1.40 and a 200 day moving average of $1.66. The stock has a market cap of $161.85 million, a P/E ratio of -1.91 and a beta of 0.97. The company has a quick ratio of 9.09, a current ratio of 9.18 and a debt-to-equity ratio of 1.61. Milestone Pharmaceuticals has a 52-week low of $1.00 and a 52-week high of $3.06.
Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) last released its earnings results on Wednesday, May 13th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.26). The business had revenue of $0.24 million during the quarter, compared to analyst estimates of $30.11 million. As a group, sell-side analysts anticipate that Milestone Pharmaceuticals will post -0.97 EPS for the current year.
Milestone Pharmaceuticals Company Profile
Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.
Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.
Featured Stories
- Five stocks we like better than Milestone Pharmaceuticals
- Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet
- 3 Overlooked Energy ETFs Delivering Strong Returns and Income
- 3 Space Stocks That Could Outshine SpaceX After Its IPO
- JPMorgan’s Q2 Strength Gives the Stock Rally New Support
Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
